Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price hit a new 52-week high on Thursday . The stock traded as high as $54.52 and last traded at $54.2750, with a volume of 739629 shares. The stock had previously closed at $50.50.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Truist Financial lifted their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wedbush reissued an “outperform” rating and set a $46.00 target price on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Finally, HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $64.43.

Dianthus Therapeutics Trading Up 0.1%

The firm’s 50-day moving average price is $43.79 and its 200 day moving average price is $35.02. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -15.34 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. Analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 216,538 shares of company stock worth $8,283,175 over the last ninety days. 8.15% of the stock is owned by insiders.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Fairmount Funds Management LLC increased its stake in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after buying an additional 600,000 shares during the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. grew its holdings in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC increased its holdings in Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.